A Phase 2 interventional study of silodosin in Nocturia and Prostatic Hyperplasia, sponsored by Watson Pharmaceuticals. Completed at 27 sites in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-03-09.
Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Nocturia with a site in United States — 7 open to participants now, 10 under way, none of them phase 3. Nocturia · United States.
Among the 57 studies in Nocturia with a site in United States, this one is the 17th largest by enrollment of the 53 interventional ones that give a count, is one of 6 that started in 2009, is one of 5 in phase 2, and was the 5th registered.
134 studies on the registry are indexed under Nocturia; 22 are open to participants now.
Browse Nocturia studies →7 of the 57 studies in Nocturia with a site in United States are open now. Recruiting first, the newest first:
University of Pittsburgh · Sites in United States
Ages 65+ · Women only
Northwell Health · Sites in United States
Ages 50–99 · Men only · Healthy volunteers
Wake Forest University Health Sciences · Sites in United States
Ages 18–80
Atlanta VA Medical Center · Sites in United States
Ages 60+
University of California, San Francisco · Sites in United States
Ages 60+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Nocturia studies recruiting now, 13 (76%) set no upper age limit and 2 (12%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 18 · Phase 4 8
First in 2004; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 71 across 108 interventional studies indexed under Nocturia.
Median enrollment 60 across the 53 interventional studies, 10 across the 4 observational. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under Watson Pharmaceuticals, one of the names counted as AbbVie. Under that name alone:
Watson Pharmaceuticals is the lead sponsor of 30 studies on the registry; none are open to participants now.
AbbVie has 1 study filed under Nocturia — fewer than ten, so there is no comparison to draw.
6 of the studies in Nocturia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06797245Medstar Health Research InstituteAPPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women | 2026-11 |
| NCT04734106Wake Forest University Health SciencesSafety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis | 2027-04 |
| NCT07829029University of California, San FranciscoAncillary Nocturnal Urinary Symptoms Analyses for TRIUMPH | 2027-05-02 |
| NCT05540392Memorial Sloan Kettering Cancer CenterAn Acupuncture Study for Prostate Cancer Survivors With Urinary Issues | 2027-09 |
| NCT05148156Northwell HealthUrolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer. | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 57 studies in Nocturia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia and nocturia. The following procedures are utilized; physical exams, electrocardiograms, clinical laboratory tests, vital signs, urinary diary, Pittsburgh Quality of Sleep Index, Nocturia Quality of Life
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: silodosin
Drug: silodosin
α1-adrenergic antagonist
Also known as: Rapaflo
Change in Nocturia Episodes
Time frame: 12 weeks
| Milestone | Silodosin 8mg | Placebo |
|---|---|---|
| Started | 111 | 98 |
| Completed | 97 | 89 |
| Not completed | 14 | 9 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 |
| episodes | Silodosin 8mg | Placebo |
|---|---|---|
| Change in Nocturia Episodes | -1.2 ± 1.35 | -1.0 ± 1.44 |
Collected over 12 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Silodosin 8mg | — | 1/111 (0.9%) | 39/111 (35.1%) |
| Placebo | — | 1/98 (1%) | 21/98 (21.4%) |
| Event | Silodosin 8mg | Placebo |
|---|---|---|
| Multiple Bone FractureMusculoskeletal and connective tissue disorders | 0/111 | 1/98 |
| CellulitisInfections and infestations | 1/111 | 0/98 |
| Event | Silodosin 8mg | Placebo |
|---|---|---|
| Retrograde EjaculationReproductive system and breast disorders | 24/111 | 0/98 |
| InsomniaPsychiatric disorders | 2/111 | 5/98 |
| HeadacheNervous system disorders | 5/111 | 1/98 |
| DiarrhoeaGastrointestinal disorders | 3/111 | 4/98 |
| Back PainMusculoskeletal and connective tissue disorders | 4/111 | 3/98 |
| DizzinessNervous system disorders | 4/111 | 3/98 |
| FatigueGeneral disorders | 4/111 | 1/98 |
| Urinary Track InfectionInfections and infestations | 0/111 | 3/98 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 3/111 | 0/98 |
| Musculoskeletal PainMusculoskeletal and connective tissue disorders | 2/111 | 2/98 |
| Age, Categorical(Participants) | Silodosin 8mg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 63 | 62 | 125 |
| >=65 years | 48 | 36 | 84 |
| Age Continuous(years) | Silodosin 8mg | Placebo | Total |
|---|---|---|---|
| Mean | 64.6 ± 8.03 | 64.2 ± 8.92 | 64.4 ± 8.44 |
| Sex: Female, Male(Participants) | Silodosin 8mg | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 111 | 98 | 209 |
| Region of Enrollment(participants) | Silodosin 8mg | Placebo | Total |
|---|---|---|---|
| United States | 111 | 98 | 209 |
The record gives a start of Jan 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin